Bio-Techne Corp (NASDAQ:TECH) Plans $0.08 Quarterly Dividend

Bio-Techne Corp (NASDAQ:TECH) declared a quarterly dividend on Wednesday, August 12th. Investors of record on Monday, August 17th will be given a dividend of 0.08 per share by the biotechnology company on Friday, August 28th. This represents a c) annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, August 17th.

Bio-Techne has a dividend payout ratio of 15.4% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Bio-Techne to earn $1.76 per share next year, which means the company should continue to be able to cover its $0.32 annual dividend with an expected future payout ratio of 18.2%.

Bio-Techne Stock Performance

NASDAQ TECH traded up $0.08 during trading hours on Wednesday, reaching $72.23. 2,358,993 shares of the company were exchanged, compared to its average volume of 3,483,642. Bio-Techne has a 1 year low of $43.19 and a 1 year high of $72.39. The business’s 50 day simple moving average is $66.18 and its 200-day simple moving average is $59.18. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $11.31 billion, a P/E ratio of 104.68, a P/E/G ratio of 8.59 and a beta of 1.28.

Bio-Techne (NASDAQ:TECH) last released its earnings results on Wednesday, August 12th. The biotechnology company reported $0.52 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.52. Bio-Techne had a net margin of 9.05% and a return on equity of 13.57%. The firm had revenue of $321.19 million for the quarter, compared to analysts’ expectations of $314.68 million. During the same period in the previous year, the company earned $0.53 earnings per share. The company’s quarterly revenue was up 1.3% on a year-over-year basis. On average, equities research analysts expect that Bio-Techne will post 1.65 earnings per share for the current year.

Bio-Techne News Roundup

Here are the key news stories impacting Bio-Techne this week:

• Positive Sentiment: Bio-Techne reported fiscal fourth-quarter revenue of $321.2 million, exceeding the $314.7 million analyst consensus. Organic revenue increased 3%, driven by stronger demand in its research and diagnostics businesses. Bio-Techne beats revenue estimates on research, diagnostics demand uptick
• Positive Sentiment: Profitability improved substantially: quarterly net income was $54.6 million, compared with a $17.7 million loss a year earlier, while full-year GAAP EPS rose to $1.16 from $0.46. Bio-Techne Q4 Revenue Rises to $321.2 Million
• Positive Sentiment: The board declared a quarterly dividend of $0.08 per share, payable August 28 to shareholders of record August 17, providing continued shareholder income. Bio-Techne Declares Dividend
• Neutral Sentiment: Adjusted EPS of $0.52 matched expectations but declined from $0.53 a year earlier. Reported revenue rose only about 1% year over year, and fiscal-year sales were approximately flat at $1.2 billion. Techne Q4 Earnings Meet Estimates
• Neutral Sentiment: Merck KGaA has agreed to acquire Bio-Techne for $73 per share in cash, implying an enterprise value of about $11.3 billion. With the stock already close to that consideration, trading is likely to be driven primarily by deal-completion expectations rather than operating results. Bio-Techne Q4 Revenue Rises to $321.2 Million

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.